Verrica Pharmaceuticals (VRCA) has a market capitalization of approximately $59M, trading at $5.55 on the NASDAQ. Market cap moves with the live share price.
Verrica Pharmaceuticals's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 3.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Verrica Pharmaceuticals runs a net profit margin of -48.0%, a gross margin of 89.5%, and an operating margin of -36.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Verrica Pharmaceuticals reported revenue of
Verrica Pharmaceuticals does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Verrica Pharmaceuticals carries a debt-to-equity ratio of 0.09x and a current ratio of 2.02x, with a market beta of 1.48. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Verrica Pharmaceuticals (VRCA) the key facts are: market cap $59M, revenue
Get Verrica Pharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.